Compare Sanofi SA (SNY) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Waste Management, Inc. — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Waste Management, Inc. trades at $217.2 (market cap $87.05B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SNY | WM | |
|---|---|---|
Market Cap | $104.06B | $87.05B |
Sector | Health | Industrials |
52-Week High | $52.34 | $246.51 |
52-Week Low | $41.33 | $196.77 |
Enterprise Value | $124.09B | $109.85B |
Dividend Yield | 5.61% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
WM trades at $217.78, down 0.55% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing Q4 2025. Revenue grew to $25.20B in 2025, with strong profitability margins. Analysts maintain a buy consensus with a $263.43 price target, though technical indicators show near-term pressure.
The outlook is supported by steady waste-service demand and sustainability investments, but high debt levels and valuation concerns pose risks. CEO transition adds uncertainty, while institutional buying signals confidence. Upside exists if execution aligns with analyst targets, but investors should weigh premium valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
